• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Cumenes

Recent Advances in the Study of 3,5-Diisopropylbenzaldehyde (CAS: 112538-48-4) and Its Applications in Chemical Biology and Pharmaceutical Research

3,5-Diisopropylbenzaldehyde (CAS: 112538-48-4) is a key intermediate in the synthesis of various bioactive compounds and pharmaceutical agents. Recent studies have highlighted its significance in the development of novel therapeutic molecules, particularly in the fields of oncology, neurology, and infectious diseases. This research brief aims to summarize the latest findings related to this compound, focusing on its chemical properties, synthetic applications, and biological activities.

One of the most notable advancements in the study of 3,5-Diisopropylbenzaldehyde is its role as a precursor in the synthesis of Schiff base ligands, which have demonstrated potent antimicrobial and anticancer properties. A 2023 study published in the Journal of Medicinal Chemistry reported the successful use of this compound in the development of a new class of metal-chelating agents that exhibit selective cytotoxicity against cancer cells while sparing normal cells. The study emphasized the compound's ability to form stable complexes with transition metals, enhancing its therapeutic potential.

In addition to its applications in oncology, 3,5-Diisopropylbenzaldehyde has also been investigated for its neuroprotective effects. Research conducted at the University of Cambridge in 2024 revealed that derivatives of this compound could inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's disease. The study suggested that the isopropyl groups in the compound play a critical role in its ability to cross the blood-brain barrier, making it a promising candidate for further drug development.

From a synthetic chemistry perspective, recent work has focused on optimizing the production of 3,5-Diisopropylbenzaldehyde to improve yield and purity. A 2023 paper in Organic Process Research & Development described a novel catalytic process that reduces the need for hazardous reagents, aligning with the growing demand for greener synthetic methodologies. This advancement is particularly relevant for industrial-scale production, where efficiency and environmental impact are key considerations.

Looking ahead, the versatility of 3,5-Diisopropylbenzaldehyde continues to inspire innovative research. Ongoing studies are exploring its potential in drug delivery systems, where its chemical stability and biocompatibility are being leveraged to develop targeted therapies. Furthermore, collaborations between academic and industrial researchers are expected to accelerate the translation of these findings into clinical applications, addressing unmet medical needs in various therapeutic areas.

In conclusion, 3,5-Diisopropylbenzaldehyde (CAS: 112538-48-4) remains a compound of significant interest in chemical biology and pharmaceutical research. Its multifaceted applications, from antimicrobial agents to neuroprotective drugs, underscore its importance in modern drug discovery. As research progresses, this compound is likely to play an even greater role in the development of next-generation therapeutics.

• 939-97-9(4-Tert-Butylbenzaldehyde)
• 34246-54-3(3-Ethylbenzaldehyde)
• 122-03-2(4-Isopropylbenzaldehyde)
• 17610-00-3(3,5-Di-tert-butylbenzaldehyde)
• 40428-87-3(1-3-(propan-2-yl)phenylethan-1-one)
• 20034-50-8(4-Cyclopropylbenzaldehyde)
• 23039-28-3(3-tert-Butylbenzaldehyde)
• 645-13-6(4'-Isopropylacetophenone)
• 34246-57-6(3-Isopropylbenzaldehyde)
• 4748-78-1(4-Ethylbenzaldehyde)